NO20091190L - Fremgangsmater og sammensetninger for behandling av kreft - Google Patents

Fremgangsmater og sammensetninger for behandling av kreft

Info

Publication number
NO20091190L
NO20091190L NO20091190A NO20091190A NO20091190L NO 20091190 L NO20091190 L NO 20091190L NO 20091190 A NO20091190 A NO 20091190A NO 20091190 A NO20091190 A NO 20091190A NO 20091190 L NO20091190 L NO 20091190L
Authority
NO
Norway
Prior art keywords
cancer
methods
compositions
treatment
hydroxylase
Prior art date
Application number
NO20091190A
Other languages
English (en)
Norwegian (no)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Cougar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091190(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cougar Biotechnology Inc filed Critical Cougar Biotechnology Inc
Publication of NO20091190L publication Critical patent/NO20091190L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20091190A 2006-08-25 2009-03-20 Fremgangsmater og sammensetninger for behandling av kreft NO20091190L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
NO20091190L true NO20091190L (no) 2009-03-20

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20091190A NO20091190L (no) 2006-08-25 2009-03-20 Fremgangsmater og sammensetninger for behandling av kreft
NO20200775A NO20200775A1 (no) 2006-08-25 2020-07-01 Fremgangsmåter og sammensetninger for behandling av kreft

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20200775A NO20200775A1 (no) 2006-08-25 2020-07-01 Fremgangsmåter og sammensetninger for behandling av kreft

Country Status (20)

Country Link
EP (3) EP2478907B1 (enExample)
JP (10) JP2010501575A (enExample)
KR (4) KR20090059126A (enExample)
CN (2) CN104306977A (enExample)
AU (6) AU2007287098C1 (enExample)
CA (1) CA2661422C (enExample)
CY (2) CY1115477T1 (enExample)
DK (2) DK2061561T3 (enExample)
ES (2) ES2869343T3 (enExample)
HR (2) HRP20130961T1 (enExample)
HU (1) HUE054495T2 (enExample)
IL (3) IL197211A0 (enExample)
LT (1) LT2478907T (enExample)
NO (2) NO20091190L (enExample)
NZ (1) NZ597830A (enExample)
PL (2) PL2061561T3 (enExample)
PT (2) PT2478907T (enExample)
RS (2) RS62034B1 (enExample)
SI (2) SI2061561T1 (enExample)
WO (1) WO2008024484A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
ES2869343T3 (es) 2006-08-25 2021-10-25 Janssen Oncology Inc Composiciones para el tratamiento del cáncer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
AU2008319767B8 (en) * 2007-10-29 2014-01-09 Takeda Pharmaceutical Company Limited Pyrrolo [1,2-C] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
CN103298345B (zh) 2011-01-11 2016-12-14 诺瓦蒂斯公司 组合
CN103857395A (zh) 2011-04-01 2014-06-11 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
EP2858631A1 (en) * 2012-06-06 2015-04-15 Novartis AG Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP3578266B1 (en) * 2013-03-15 2024-06-19 Sun Pharmaceutical Industries Limited Abiraterone acetate formulation
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
CA2908815A1 (en) * 2013-04-04 2014-10-09 Exelixis, Inc. Drug combinations to treat cancer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US20160235714A1 (en) * 2013-10-01 2016-08-18 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
CN109674801A (zh) * 2013-10-01 2019-04-26 诺华股份有限公司 组合
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
ES2863500T3 (es) * 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
NZ763947A (en) 2017-10-16 2025-12-19 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
IL286048B2 (en) * 2019-03-06 2025-03-01 Propella Therapeutics Inc Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
WO2021209945A1 (en) * 2020-04-16 2021-10-21 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69327096T2 (de) 1992-03-31 2000-06-21 Btg International Ltd., London 17-substituierte steroide, verwendbar bei behandlung von krebs
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO2001064251A2 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
ES2298570T3 (es) * 2002-10-23 2008-05-16 Pantarhei Bioscience B.V. Composiciones farmaceuticas que comprenden derivados de estetrol para el uso en la terapia del cancer.
US20050054620A1 (en) * 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
ES2869343T3 (es) 2006-08-25 2021-10-25 Janssen Oncology Inc Composiciones para el tratamiento del cáncer

Also Published As

Publication number Publication date
JP6445123B2 (ja) 2018-12-26
NO20200775A1 (no) 2009-03-20
WO2008024484A1 (en) 2008-02-28
JP2010501575A (ja) 2010-01-21
CA2661422C (en) 2017-06-27
CY1124221T1 (el) 2022-05-27
AU2015221447B2 (en) 2016-12-15
IL227746A0 (en) 2013-09-30
EP2061561A1 (en) 2009-05-27
NZ597830A (en) 2013-02-22
JP2022185091A (ja) 2022-12-13
CY1115477T1 (el) 2017-01-04
HK1131577A1 (en) 2010-01-29
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
CN104306977A (zh) 2015-01-28
EP2478907A2 (en) 2012-07-25
RS62034B1 (sr) 2021-07-30
AU2007287098C1 (en) 2018-03-15
JP2015110577A (ja) 2015-06-18
KR20180003636A (ko) 2018-01-09
IL197211A0 (en) 2009-12-24
JP2024164147A (ja) 2024-11-26
EP3804730A1 (en) 2021-04-14
SI2478907T1 (sl) 2021-08-31
KR20150108946A (ko) 2015-09-30
AU2022206696A1 (en) 2022-08-11
PL2478907T3 (pl) 2021-10-25
AU2007287098A1 (en) 2008-02-28
PL2061561T3 (pl) 2013-12-31
LT2478907T (lt) 2021-06-25
DK2478907T3 (da) 2021-05-25
AU2007287098B2 (en) 2013-08-15
HRP20210670T1 (hr) 2021-06-11
RS52956B (sr) 2014-02-28
JP6740497B2 (ja) 2020-08-12
KR20090059126A (ko) 2009-06-10
IL257681A (en) 2018-04-30
JP2018065859A (ja) 2018-04-26
JP2019059750A (ja) 2019-04-18
JP2021038252A (ja) 2021-03-11
CA2661422A1 (en) 2008-02-28
EP2478907B1 (en) 2021-04-14
HUE054495T2 (hu) 2021-09-28
EP2478907A3 (en) 2012-08-01
PT2478907T (pt) 2021-05-26
DK2061561T3 (da) 2013-10-07
AU2015221447B9 (en) 2017-07-20
JP2020114851A (ja) 2020-07-30
ES2428634T3 (es) 2013-11-08
AU2015221447A1 (en) 2015-09-17
SI2061561T1 (sl) 2013-11-29
JP6053279B2 (ja) 2016-12-27
JP2012082215A (ja) 2012-04-26
ES2869343T3 (es) 2021-10-25
AU2018271331A1 (en) 2018-12-20
HRP20130961T1 (hr) 2013-11-22
PT2061561E (pt) 2013-10-09
JP2017052791A (ja) 2017-03-16
CN101528308A (zh) 2009-09-09
AU2017201764A1 (en) 2017-04-06
KR20200125776A (ko) 2020-11-04

Similar Documents

Publication Publication Date Title
NO20091190L (no) Fremgangsmater og sammensetninger for behandling av kreft
Rehman et al. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme
Mihailidou et al. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction
Weerachayaphorn et al. Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine
ID26781A (id) Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer
NO20065442L (no) Amidoforbindelser og deres anvendelse som legemidler
Chetrite et al. The selective estrogen enzyme modulator (SEEM) in breast cancer
IN2012DN04867A (enExample)
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
Xiong et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines
NO20062679L (no) Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
SE0400346D0 (sv) Steroids for cancer treatment
Dhondt et al. Abiraterone and spironolactone in prostate cancer: a combination to avoid
Hirsova et al. Cholestatic effect of epigallocatechin gallate in rats is mediated via decreased expression of Mrp2
EP1857112A4 (en) AGAINST CANCER FOR ORAL USE WITH LIPOSOME-CONTAINING PHYTOSTEROLS AND PREVENTION OR TREATMENT OF CANCER WITH LIPOSOM
Wang et al. Nicotine induced CpG methylation of Pax6 binding motif in StAR promoter reduces the gene expression and cortisol production
Komori et al. Ursodeoxycholic acid inhibits overexpression of P-glycoprotein induced by doxorubicin in HepG2 cells
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
CY1105607T1 (el) Η χρηση ενος η1 ανταγωνιστη και ριμεξαολης ως ενα ασφαλες στεροειδες για την θεραπεια ρινιτιδας
Samarajeewa et al. Promoter-specific effects of metformin on aromatase transcript expression
Fiandalo et al. Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer
Xu et al. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells
Kaufmann et al. Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study
Wang et al. Pharmacological concentration of resveratrol suppresses aromatase in JEG-3 cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application